467 related articles for article (PubMed ID: 23087179)
1. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A
Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179
[TBL] [Abstract][Full Text] [Related]
2. Canakinumab in Schnitzler syndrome.
Vanderschueren S; Knockaert D
Semin Arthritis Rheum; 2013 Feb; 42(4):413-6. PubMed ID: 22901459
[TBL] [Abstract][Full Text] [Related]
3. The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome.
de Koning HD; Schalkwijk J; Stoffels M; Jongekrijg J; Jacobs JF; Verwiel E; Koenen HJ; Preijers F; Holzinger D; Joosten I; van der Meer JW; Simon A
Arthritis Res Ther; 2015 Jul; 17(1):187. PubMed ID: 26198339
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study.
Krause K; Tsianakas A; Wagner N; Fischer J; Weller K; Metz M; Church MK; Maurer M
J Allergy Clin Immunol; 2017 Apr; 139(4):1311-1320. PubMed ID: 27658762
[TBL] [Abstract][Full Text] [Related]
5. A Case of Schnitzler's Syndrome without Monoclonal Gammopathy-Associated Chronic Urticaria Treated with Anakinra.
Ahn MJ; Yu JE; Jeong J; Sim DW; Koh YI
Yonsei Med J; 2018 Jan; 59(1):154-157. PubMed ID: 29214791
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
Imagawa T; Nishikomori R; Takada H; Takeshita S; Patel N; Kim D; Lheritier K; Heike T; Hara T; Yokota S
Clin Exp Rheumatol; 2013; 31(2):302-9. PubMed ID: 23380020
[TBL] [Abstract][Full Text] [Related]
7. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
[TBL] [Abstract][Full Text] [Related]
8. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome.
de Koning HD; Bodar EJ; Simon A; van der Hilst JC; Netea MG; van der Meer JW
Ann Rheum Dis; 2006 Apr; 65(4):542-4. PubMed ID: 16096327
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
[TBL] [Abstract][Full Text] [Related]
10. [Schnitzler's syndrome: a case report and literature review of the response to treatment with anakinra].
Benítez Gutiérrez L; Mellor Pita S; Tutor de Ureta P; Yebra Bango M
Med Clin (Barc); 2013 May; 140(9):427-8. PubMed ID: 23177777
[No Abstract] [Full Text] [Related]
11. Retention rate of IL-1 inhibitors in Schnitzler's syndrome.
Crisafulli F; Vitale A; Airò P; Grigis M; Gaggiano C; Dagna L; Cavalli G; Cimaz R; Viapiana O; Iannone F; Lopalco G; Bortolotti R; Abdel Jaber M; Montecucco C; Monti S; Balduzzi S; Emmi G; Mattioli I; Franceschini F; Cantarini L; Frassi M
Clin Exp Rheumatol; 2022 Nov; 40(11):2011-2017. PubMed ID: 35084307
[TBL] [Abstract][Full Text] [Related]
12. Schnitzler's Syndrome-Diagnostic Experience, Approaches to Therapy, and Patient Management according to a Multicenter Russian Cohort.
Salugina SO; Torgashina AV; Borzova EY; Rameev VV; Gorodetsky VR; Fedorov ES; Muravyova NV
Dokl Biochem Biophys; 2024 Jun; ():. PubMed ID: 38861148
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of interleukin-1 blockade in Schnitzler's syndrome without detectable monoclonal gammopathy: a case-based review.
Bixio R; Rossini M; Giollo A
Clin Rheumatol; 2021 Jul; 40(7):2973-2977. PubMed ID: 33175311
[TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study.
Néel A; Henry B; Barbarot S; Masseau A; Perrin F; Bernier C; Kyndt X; Puechal X; Weiller PJ; Decaux O; Ninet J; Hot A; Aouba A; Astudillo L; Berthelot JM; Bonnet F; Brisseau JM; Cador B; Closs-Prophette F; Dejoie T; de Korwin JD; Dhote R; Fior R; Grosbois B; Hachulla E; Hatron PY; Jardel H; Launay D; Lorleac'h A; Pottier P; Moulis G; Serratrice J; Smail A; Hamidou M
Autoimmun Rev; 2014 Oct; 13(10):1035-41. PubMed ID: 25220180
[TBL] [Abstract][Full Text] [Related]
15. Schnitzler's syndrome: diagnosis, treatment, and follow-up.
Simon A; Asli B; Braun-Falco M; De Koning H; Fermand JP; Grattan C; Krause K; Lachmann H; Lenormand C; Martinez-Taboada V; Maurer M; Peters M; Rizzi R; Rongioletti F; Ruzicka T; Schnitzler L; Schubert B; Sibilia J; Lipsker D
Allergy; 2013; 68(5):562-8. PubMed ID: 23480774
[TBL] [Abstract][Full Text] [Related]
16. Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome.
Gorodetskiy VR; Salugina SO; Fedorov ES
Case Rep Rheumatol; 2018; 2018():5416907. PubMed ID: 29850358
[TBL] [Abstract][Full Text] [Related]
17. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
[TBL] [Abstract][Full Text] [Related]
18. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.
Gattorno M; Obici L; Cattalini M; Tormey V; Abrams K; Davis N; Speziale A; Bhansali SG; Martini A; Lachmann HJ
Ann Rheum Dis; 2017 Jan; 76(1):173-178. PubMed ID: 27269295
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients.
Yokota S; Imagawa T; Nishikomori R; Takada H; Abrams K; Lheritier K; Heike T; Hara T
Clin Exp Rheumatol; 2017; 35 Suppl 108(6):19-26. PubMed ID: 27974104
[TBL] [Abstract][Full Text] [Related]
20. A case of Schnitzler's syndrome without monoclonal gammopathy successfully treated with canakinumab.
Fujita Y; Asano T; Sakai A; Norikawa N; Yamamoto T; Matsumoto H; Sato S; Temmoku J; Yashiro-Furuya M; Matsuoka N; Watanabe H; Migita K
BMC Musculoskelet Disord; 2021 Mar; 22(1):257. PubMed ID: 33685423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
